A novel predictive and prognostic signature, named chemoresist, was developed to assess the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) post-surgery and adjuvant chemotherapy. In a multicohort analysis, significant survival differences were noted between high and low chemoresist patients, with median overall survival reaching 42 months in low chemoresist groups, compared to just 17 months in high groups. This signature outperformed traditional TNM staging and identified patients likely to benefit from chemotherapy.
Multicenter Study by Huang L, Han Q (…) Shi Y et 3 al. in Ann Surg
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.